REGN250103P540000
- 2.13
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Regeneron Expands Eye Care Focus With Oxular Buyout
Santa Claus Came Without Rallying the Troops | Live Stock
Regeneron Pharmaceuticals' (NASDAQ:REGN) Investors Will Be Pleased With Their Decent 89% Return Over the Last Five Years
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt
Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Regeneron Reports Positive Results for Two Anti-coagulant Drugs